Number of participants according to co-diagnoses 3 years before participant's index were reported in this outcome measure. Index date was defined as the date of treatment initiation for mRCC. Co-diagnoses were based on International Classification of Diseases 10th revision (ICD-10) codes. One participant may have more than one co-diagnoses.

All eligible advanced/metastatic RCC participants who initiated treatment for mRCC were included. This analysis was planned only in the treated mRCC participants.

Number of participants according to co-diagnoses up to 3 years after participant's index were reported in this outcome measure. Index date was defined as the date of treatment initiation for mRCC. Co-diagnoses were based on ICD-10 codes. One participant may have more than one co-diagnoses.

All eligible advanced/metastatic RCC participants who initiated treatment for mRCC were included. This analysis was planned only in the treated mRCC participants.

BMI of participants at index was reported in this outcome measure. Index date was defined as the date of treatment initiation for mRCC.

All eligible participants were included. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.

The number of outpatient visits and emergency room (ER) visits per patient year for all contacts, disease-specific contacts and other contacts were reported in this outcome measure. All contacts included disease specific contacts and other contacts. Per patient year was defined as total sum of events divided by the total sum of follow-up length of the participants.

All eligible advanced/metastatic RCC participants who initiated treatment for mRCC were included.

The number of hospitalization visits per patient year for all contacts, disease-specific contacts and other contacts were reported in this outcome measure. All contacts included disease specific contacts and other contacts. Per patient year was defined as total sum of events divided by the total sum of follow-up length of the participants.

All eligible advanced/metastatic RCC participants who initiated treatment for mRCC were included.

Number of procedures and surgeries per patient year were reported in this outcome measure. Per patient year was defined as total sum of events divided by the total sum of follow-up length of the participants.

All eligible advanced/metastatic RCC participants who initiated treatment for mRCC were included.

Number of participants receiving each treatment per treatment line were reported in this outcome measure.

All eligible advanced/metastatic RCC participants who initiated treatment for mRCC were included.

Number of participants according to treatment per treatment line between 2010 to 2017 were reported in this outcome measure.

All eligible advanced/metastatic RCC participants who initiated treatment for mRCC were included.

Number of participants according to treatment per treatment line between 2018 to 2021 were reported in this outcome measure.

All eligible advanced/metastatic RCC participants who initiated treatment for mRCC were included.

Number of laboratory days per patient year were reported in this outcome measure. Per patient year was defined as total sum of events divided by the total sum of follow-up length of the participants.

All eligible advanced/metastatic RCC participants who initiated treatment for mRCC were included.

Number of laboratory days per patient year stratified by IMDC risk category were reported in this outcome measure. IMDC risk category included Score 0= favorable risk, no missing values allowed; Score 1-2= intermediate risk, total score=1: maximum 1 risk factor can have missing value, total score=2: no missing values allowed; Score 3-6= poor risk, maximum 3 risk factors allowed to have missing values; Unknown risk= when none of the above risk categories could be assigned. Per patient year was defined as total sum of events divided by the total sum of follow-up length of the participants.

All eligible advanced/metastatic RCC participants who initiated treatment for mRCC were included. Here, 'Number Analyzed' signifies participants evaluable for the specified rows.

KPS:used for rating activities of daily living on 11-step scale from 0-100,higher score=participant better able to carry daily activities.Score:100=normal no complaints;no disease evidence,90=able to carry normal activity;minor signs/symptoms of disease,80=normal activity with effort;some signs/symptoms, 70=cares for self;unable to carry normal activity,60=required occasional assistance,able to care for personal needs,50=required considerable assistance & frequent medical care,40=disabled;required special care/assistance,30=severely disabled;hospital admission indicated;20=very sick;hospital admission necessary,10=moribund & 0=dead.IMDC risk category:0=favorable risk,no missing values allowed;1-2=intermediate risk,total score=1:max 1 risk factor could have missing value,total score=2:no missing values allowed;3-6=poor risk,max 3 risk factors allowed to have missing values; Unknown=none of the above risk categories could be assigned.Index date=date of treatment initiation for mRCC.

All eligible advanced/metastatic RCC participants who initiated treatment for mRCC were included.

Number of participants classified according to PAD were reported in this outcome measure. Histology included chromophobe renal cell carcinoma, clear cell renal cell carcinoma, oncocytoma renal cell carcinoma, papillary renal cell carcinoma, other (chromophobe, oncocytoma, and papillary renal cell carcinoma included if not reported separately) and missing. Index date was defined as the date of treatment initiation for mRCC.

All eligible participants were included. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.

Overall Survival was defined as the time from index (start of each treatment line) until death due to any cause or end of study. Overall survival according to treatment lines (1, 2 or 3) was presented in this outcome measure.

All eligible advanced/metastatic RCC participants who initiated treatment for mRCC were included. Here, 'Number Analyzed' signifies participants evaluable for the specified rows.

Time to next treatment (TTNT) was defined as the interval between the start of current treatment and the start of the next-line treatment or death or end of study. Kaplan-Meier method was used for analysis. TTNT according to treatment lines were presented in this outcome measure.

All eligible advanced/metastatic RCC participants who initiated treatment for mRCC were included. Here, 'Number Analyzed' signifies participants evaluable for the specified rows.

Number of participants classified according to IMDC risk group status at initiation of treatment were reported in this outcome measure. IMDC risk category included score 0= favorable risk, no missing values allowed; score 1-2= Intermediate risk, total score=1: maximum 1 risk factor can have missing value, total score=2: no missing values allowed; Score 3-6= Poor risk, maximum 3 risk factors allowed to have missing values; Unknown risk= when none of the above risk categories could be assigned. Index date was defined as the date of treatment initiation for mRCC.

All eligible advanced/metastatic RCC participants who initiated treatment for mRCC were included.

Absolute costs associated with healthcare resource utilization for all contacts, disease-specific contacts and other contacts was reported in this outcome measure. All contacts included ER visits, hospitalizations, and outpatient contacts.

All eligible advanced/metastatic RCC participants who initiated treatment for mRCC were included.